<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398463</url>
  </required_header>
  <id_info>
    <org_study_id>TCA-01-III</org_study_id>
    <nct_id>NCT00398463</nct_id>
  </id_info>
  <brief_title>Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance</brief_title>
  <acronym>3T/2R</acronym>
  <official_title>Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether adding tirofiban, administered at high bolus dose on top of
      aspirin and clopidogrel will lead to a lower rate of periprocedural myocardial infarction
      after percutaneous coronary intervention in elective patients presenting with aspirin and/or
      clopidogrel resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the effect of treatment with a high bolus dosage of Tirofiban (in
      addition to Aspirin, Heparin and 300mg or 600mg clopidogrel) on the rate of periprocedural
      myocardial infarction compared to Aspirin, Heparin (or bivalirudin) and 300mg or 600mg
      clopidogrel alone in patients resistant to aspirin and/or to clopidogrel.

      This is a randomized, double blind, placebo controlled (with bailout tirofiban as rescue)
      multicenter study. Enrollment will last between 12 and 36 months depending on the final
      number of participating centres. The minimum follow-up will be 30 days after the index
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin I or T elevation ratio at least three times the upper limit of normal.</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of myocardial infarction defined as elevation of CK-MB &gt;1, ≥3 or ≥5 times the ULN in one or more blood sample(s).</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevation of troponin levels above upper limit of normal in ratios different from the primary endpoint</measure>
    <time_frame>within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding rates</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>with the first year of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of major adverse cardiovascular events</measure>
    <time_frame>at 30 days and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <description>Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glycoprotein IIb/IIIa inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline infusion will be administered for 14-24 hours</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Glycoprotein IIb/IIIa inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All Patients older than 18 years scheduled for coronary angiography and/or PCI will be
             enrolled. [Patients should be CK-MB negative (to avoid CK washout with
             revascularization) and also cTnI/T negative whereas other high-risk features will not
             lead to patient exclusion.

          2. All consecutive patients with stable or unstable troponin and CK-MB negative coronary
             artery disease showing aspirin and or clopidogrel resistance (ACR) will be enrolled.
             These include:

               -  Patients with clinical indication to undergo angiography for possible
                  revascularisation.

               -  Patients with ACR in whom catheter-based coronary intervention is planned based
                  on previous angiogram.

        Exclusion Criteria:

          1. Patients who can not give informed consent or have a life expectancy of &lt; 1 year

          2. Evolving or Ongoing myocardial infarction (MI) (Persistence of or developing Q wave or
             ST segment elevation at ECG with or without typical chest pain or typical rapid rise
             and fall CK-MB or new LBBB) or patients in whom the treating physician intends to use
             a Gp IIB/IIIa inhibitors.

          3. Administration of any GP IIb/IIIa receptor antagonist, anticoagulation, or lytic
             therapy in the previous 30 days

          4. Serum creatinine more than 2.5 mg/dl (221 micromol/L)

          5. Ongoing bleeding or bleeding diathesis or contraindication for anticoagulation or
             increase bleeding risk or history of bleeding in the last 1 year

          6. Previous stroke or TIA or any intracranial pathology in the last six months

          7. Major surgery or trauma within the previous six weeks

          8. Platelet count &lt; 100.000 per cubic mm or HCT ,33% or Hb &lt; 11 gm/dL

          9. Subjects who received low-molecular-weight heparin within the 24 hours prior to
             randomization

         10. Subjects with an allergy or intolerance to aspirin, heparin, clopidogrel, or tirofiban

         11. Patients with severe hypertension (SBP &gt; 180 mm Hg or DBP &gt; 110 mm Hg) or in
             cardiogenic shock (SBP 80 mm Hg or below for &gt; 30 minutes) or requiring IABP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Ferrara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <state>Fe</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004 Mar 17;43(6):1122-6.</citation>
    <PMID>15028378</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004 Jul 7;44(1):14-9.</citation>
    <PMID>15234398</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marco Valgimigli</name_title>
    <organization>Azienda Ospedaliera Universitaria di Ferrara</organization>
  </responsible_party>
  <keyword>tirofiban</keyword>
  <keyword>aspirin resistance</keyword>
  <keyword>clopidogrel resistance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Krestin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

